A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
Public ClinicalTrials.gov record NCT05585632. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age
Study identification
- NCT ID
- NCT05585632
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Enrollment
- 392 participants
Conditions and interventions
Conditions
Interventions
- mRNA-1010 Biological
- mRNA-1345 Biological
- mRNA-1273.214 Biological
- mRNA-1045 Biological
- mRNA-1230 Biological
Biological
Eligibility (public fields only)
- Age range
- 50 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2022
- Primary completion
- Feb 27, 2024
- Completion
- Feb 27, 2024
- Last update posted
- Mar 7, 2024
2022 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Accel Research Sites | DeLand | Florida | 32720 | — |
| Research Centers of America (cenexel) | Hollywood | Florida | 33024 | — |
| Accel Research Sites | St. Petersburg | Florida | 33709 | — |
| Atlanta Center for Medical Research - Family Medicine | Atlanta | Georgia | 30331 | — |
| Centricity Research | Columbus | Georgia | 31904 | — |
| Cenexel IRA (iResearch Atlanta) | Decatur | Georgia | 30030 | — |
| Optimal Research | Peoria | Illinois | 61614 | — |
| DM Clinical Research | Southfield | Michigan | 48076 | — |
| Lucas Research, Inc. (Diabetes & Endocrinology Consultants PC) | Morehead City | North Carolina | 28557 | — |
| Trial Management Associates | Wilmington | North Carolina | 28403 | — |
| Velocity Clinical Research | Anderson | South Carolina | 29621 | — |
| Trial Management Associates | Myrtle Beach | South Carolina | 29572 | — |
| DM Clinical Research | Houston | Texas | 77081 | — |
| DM Clinical Research | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05585632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05585632 live on ClinicalTrials.gov.